Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon

Yvonne E. Chiu, Beth A. Drolet, Francine Blei, Manuel Carcao, Jason Fangusaro, Michael E. Kelly, Alfons Krol, Sabra Lofgren, Anthony J. Mancini, Denise W. Metry, Michael Recht, Robert A. Silverman, Wynnis L. Tom, Elena Pope

Research output: Contribution to journalArticlepeer-review

87 Scopus citations

Abstract

Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.

Original languageEnglish (US)
Pages (from-to)934-938
Number of pages5
JournalPediatric Blood and Cancer
Volume59
Issue number5
DOIs
StatePublished - Nov 2012

Keywords

  • Kaposiform hemangioendothlioma
  • Kasabach-Merritt
  • Propranolol
  • Treatment
  • Tufted angioma
  • Vascular tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon'. Together they form a unique fingerprint.

Cite this